Dr. Reddy’s Allots 12,665 ESOP Shares, Nudging Up Equity Capital
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Dr Reddy’s Laboratories ( (RDY) ).
On February 17, 2026, Dr. Reddy’s Laboratories allotted 12,665 fully paid equity shares of Re.1 each to eligible employees following the exercise of stock options under its 2002 Employee Stock Options Scheme and 2007 ADR Stock Option Scheme. This ESOP-driven issuance, priced at varying exercise levels, raised the company’s total issued share capital to Rs. 83.46 crore, marginally diluting existing holdings while reinforcing employee alignment with shareholder value through share-based incentives.
The newly issued shares are ordinary equity shares ranking pari passu with existing stock and carry the same rights, with no lock-in conditions attached. The modest increase in share count underscores Dr. Reddy’s ongoing use of equity-linked compensation as a standard tool in its capital and talent management framework, with limited impact on overall capital structure but continued signalling of commitment to key employees across its domestic and ADR-listed platforms.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is an Indian pharmaceutical company based in Hyderabad, Telangana, with equity shares listed on BSE, the National Stock Exchange of India, and American Depositary Receipts traded on the New York Stock Exchange and NSE IFSC. The company operates in the global generics and active pharmaceutical ingredients space, using stock-based compensation schemes as part of its employee incentive and retention strategy.
Average Trading Volume: 1,464,003
Technical Sentiment Signal: Buy
Current Market Cap: $11.65B
For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.
